Phase 2a Study of VTX3232 in Parkinson's Disease

Inclusion Criteria: * Participants must be ≥ 40 years up to 80 years of age, inclusive, at the time of signing the informed consent, with BMI \> 18.5 and \< 32.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females. * Diagnosis of idiopathic Parkinson's Disease between 0 and 60 months prior to screening. * Score of 2 or less on Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV at screening. * Have not received prior treatment with deep brain stimulation (DBS). * If receiving treatment with symptomatic PD therapies, treatment must be stable. Note: The Medical Monitor should be contacted with any questions regarding concomitant therapies. * A female participant is eligible if they are of nonchildbearing potential * A male participant sexually active with a woman of child bearing potential is eligible if they agree to use contraception/barrier and refrain from donating sperm during the study and for at least 90 days after the last dose Exclusion Criteria: * Diagnosis of a Parkinsonian syndrome other than idiopathic Parkinson's Disease. * A diagnosis of a significant central nervous system (CNS) disease other than Parkinson's disease; history of repeated head injury or traumatic brain injury; history of epilepsy or seizure disorder other than febrile seizures as a child. * History of brain surgery.